ASLAN Pharmaceuticals Announces Series of KOL Events to Discuss Atopic Dermatitis Treatment Landscape and ASLAN004

0

– Management will host the first in a series of KOL webinars starting Monday, October 25, 2021 at 10:00 a.m.ET

– First patient in the global phase 2b study of 300 patients on ASLAN004 on track for recruitment in 4Q 2021

MENLO PARK, Calif. And SINGAPORE, Oct. 18, 2021 (GLOBE NEWSWIRE) – ASLAN Pharmaceuticals (Nasdaq: ASLN), an immunology-focused clinical-stage biopharmaceutical company that develops innovative treatments to transform patients’ lives, announced today ‘hui that it will host the first in a series of Key Opinion Leader (KOL) events on the emerging landscape of atopic dermatitis treatment, as well as a review of the recently announced first positive data from its randomized, duplicate study. blind, placebo-controlled, 8 week duration, Phase 1 multiple escalating dose (MAD) study of ASLAN004 for the treatment of moderate to severe atopic dermatitis (AD). ASLAN004 is a potential first-class monoclonal antibody that targets the IL-13 receptor and has the potential to have a differentiated profile in terms of convenience, safety and efficacy.

Dr. Jonathan Silverberg, MD PhD MPH, will be the first to speak during the series on Monday, October 25, 2021 at 10:00 a.m.ET. A from ASLAN4 The series: Aspects of Atopic Dermatitis and ASLAN004 will feature other thought leaders in the coming months to discuss the changing landscape of atopic dermatitis.

About the KOL presented

Jonathan Silverberg, MD PhD MPH is Associate Professor of Dermatology in the School of Medicine and Health Sciences at George Washington University in Washington, DC, where he is Director of Clinical Research and Contact Dermatitis.

Dr Silverberg is an expert in inflammatory skin diseases with an interest in atopic and contact dermatitis. He has extensive experience in the advanced management of atopic dermatitis, hand eczema, chronic itching, psoriasis, hidradenitis and other chronic inflammatory skin disorders. He is also a national expert in allergy patch testing, phototest and photo patchtest.

Dr Silverberg completed his undergraduate education and medical training in the highly selective dual BA / MD program at the State University of New York Downstate Medical Center, Brooklyn, as well as his doctorate in neuroimmunology and his masters in public health. He completed his dermatology residency at St. Luke’s-Roosevelt Hospital Center and Beth Israel Medical Centers in New York, NY and served as Chief Resident in his final year.

Dr. Silverberg’s research interests include drug development, clinical trial design, biomarkers, dermatoepidemiology, health services research, patient-reported outcomes, co-morbidities and the burden of itching. and inflammatory skin diseases and evidence-based dermatology. His publications include over 600 peer-reviewed articles, abstracts and book chapters. He is also the author of the Clinical Management of Atopic Dermatitis (2018) manual.

Dr Silverberg has been a local, national and / or international principal investigator for numerous clinical trials investigating new treatments for atopic dermatitis and other inflammatory disorders. He has received several accolades, including the Young Leadership Award from the American Dermatological Association in 2017, the Teacher of the Year Award in the Department of Dermatology in 2015, the Outstanding Teacher Award from the Feinberg School of Medicine in 2016, 2017 and 2018, and the first Rajka Prize of the International Society for Atopic Dermatitis in 2014. He is associate editor of the Journal of the American Academy of Dermatology, British Journal of Dermatology, and current dermatology reports. Dr Silverberg is a member of the International Eczema Council and the North American Contact Dermatitis Group – the American Society of Contact Dermatitis. Dr Silverberg is also chair of the annual global multidisciplinary Revolutionizing Atopic Dermatitis conference.

Summary of the results of the recently announced ASLAN004 key study

Data published last month from a Phase 1b MAD trial demonstrated that key primary and secondary endpoints were met and conclusively established proof of concept, supporting the potential of ASLAN004 as that new differential treatment of AD.

In the ITT population, ASLAN004 achieved statistically significant improvement (p 1) compared to placebo in the primary endpoint of the effectiveness of the percentage change from inclusion in the Eczema Severity Index (EASI) and showed greater improvement compared to placebo in the key effectiveness evaluation criteria. ASLAN004 also showed significant improvements (p 1) in other key efficacy endpoints: EASI-50, EASI-75, peak pruritus and patient-oriented eczema measurement (POEM). It is important to note that ASLAN004 was shown to be well tolerated at all doses without any case of conjunctivitis in the expansion cohort.

ASLAN is on track to enroll the first patient in its 300-patient, global Phase 2b study of ASLAN004 for the treatment of AD in 4Q 2021.

How to join

To access the live event, click here or visit the “Events and Presentations” section of the ASLAN Investor Relations website at http://ir.aslanpharma.com/. A replay will be archived for 3 months immediately after the event.

Media and IR contacts

About ASLAN Pharmaceuticals

ASLAN Pharmaceuticals (Nasdaq: ASLN) is a clinical-stage immunology-focused biopharmaceutical company that develops innovative treatments to transform patients’ lives. ASLAN is currently evaluating ASLAN004, a potential first-class antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, a potent oral inhibitor of DHODH, which is under development for autoimmune diseases. ASLAN has a team in Menlo Park, California, and Singapore. For more information, please visit www.aslanpharma.com or follow ASLAN on LinkedIn.

About ASLAN004
ASLAN004 is a potential novel first-order monoclonal antibody that targets the IL-13 receptor α1 subunit (IL-13Rα1), a component of the type 2 receptor. By blocking the type 2 receptor, ASLAN004 prevents the signaling by interleukin 4 (IL-4) and interleukin 13 (IL-13), the main drivers of inflammation, at the heart of triggering allergy symptoms in atopic dermatitis, such as redness and itchy skin and in other atopic diseases. We believe that this unique blocking action of the IL-13 receptor rather than the IL-4 receptor has the potential to improve efficacy, safety and dosing regimen. ASLAN004 is the only IL-13Rα1 inhibitor in clinical development for the treatment of AD.

Forward-looking statements

This press release contains forward-looking statements. These statements are based on the beliefs and current expectations of the management of ASLAN Pharmaceuticals Limited and / or its affiliates (the “Company”). These forward-looking statements may include, without limitation, statements regarding the Company’s business strategy and clinical development plans; the Company’s plans to develop and commercialize ASLAN004; the safety and efficacy of ASLAN004, including its potential to be best-in-class; the Company’s plans and expected schedule with respect to clinical trials, clinical trial enrollment and clinical trial results for ASLAN004; and the potential of ASLAN004 as a first-order treatment for atopic dermatitis. The Company’s estimates, projections and other forward-looking statements are based on management’s current assumptions and expectations regarding future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and inherently involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements due to numerous risks and uncertainties, including unexpected safety or efficacy data observed during preclinical or clinical studies; lower than expected clinical site activation rates or clinical trial enrollment rates; the impact of the COVID-19 pandemic on the Company’s operations and the global economy; general market conditions; changes in the competitive landscape; and the Company’s ability to obtain sufficient funding to fund its strategic and clinical development plans. Other factors that could cause actual results to differ from those expressed or implied in these forward-looking statements are described in the documents and reports of the United States Securities and Exchange Commission (Commission File No. 001-38475), including the annual report of the Company on form. 20-F filed with the United States Securities and Exchange Commission on April 23, 2021. All statements other than statements of historical fact are forward-looking statements. The words “believe”, “see”, “can”, “could”, “could”, “can”, “aim”, “estimate”, “continue”, “anticipate”, “intend”, ” expect “,” plan “or the negative of these terms, and similar expressions that convey uncertainty about future events or results are intended to identify estimates, projections and other forward-looking statements. Estimates, projections and other forward-looking statements speak only as of the date on which they were made and, except to the extent required by law, the Company assumes no obligation to update or revise any estimate, projection or forward-looking statement.


Source link

Share.

Comments are closed.